Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tscan Therapeutics Inc (NQ: TCRX )

5.290 +0.210 (+4.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tscan Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Via Benzinga
The Analyst Landscape: 7 Takes On TScan Therapeutics
Via Benzinga
Key Takeaways From TScan Therapeutics Analyst Ratings
Via Benzinga
Unveiling 4 Analyst Insights On TScan Therapeutics
Via Benzinga
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics: Q4 Earnings Insights
Via Benzinga
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Closing of Upsized Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator. 
Via InvestorPlace
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS